Janney Montgomery Scott initiated coverage of Abcam plc (LSE:ABC) with a “buy” rating and fair value estimate of £17. The stock closed at £14.72 on July 1.
H.C. Wainwright initiated coverage of Principia Biopharma (NASDAQ:PRNB) with a “buy” rating and $55 price target. The stock closed at $37.61, up $4.42, on July 1.
Dawson James Securities initiated coverage of IsoRay (NYSE American:ISR) with a “buy” rating and $1 price target. The stock closed at 41 cents on July 1.
Roth Capital Partners launched coverage of Fortress Biotech (NASDAQ:FBIO), which acquires and develops biopharmaceutical assets, with a “buy” rating and price target of $4. The stock closed at $1.55 on July 1.
Roth Capital Partners launched coverage of Netherlands-based Merus NV (NASDAQ:MRUS) with a “buy” rating and $20 price target. The stock closed at $14.12 on June 27.
Maxim Group downgraded Atossa Genetics (NASDAQ:ATOS) to “hold” from “buy” and removed its previous price target of $9 after the company reported results from its Phase 2 study evaluating topical endoxifen in patients...
GMP Securities initiated coverage of Zenabis Global (TSX:ZENA) with a “buy” rating and price target of $3.25. The stock was quoted at $1.29 in afternoon trading on June 27.
SVB Leerink downgraded Aclaris Therapeutics (NASDAQ:ACRS) to “market perform” from “outperform” and slashed its price target to $4 from $13 after the failure of the company’s topical treatment for alopecia areata, an...